BPC-157 (5 mg Vial) Dosage Protocol
BPC-157 (Body Protection Compound 157) is a 15-amino-acid peptide derived from a protective sequence in human gastric juice. Preclinical research demonstrates wide-ranging effects on tendon, ligament, gut, and vascular healing. This page covers the 5 mg vial.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous | Frequency: Once or twice daily | Half-life: ~30 minutes (extended local effect)
Standard Approach (3 mL = 1.67 mg/mL)
Reconstituting with 3 mL bacteriostatic water produces a concentration of 1.67 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 200 mcg | 12 units | 0.12 mL | 25 doses |
| Weeks 3–4 | 400 mcg | 24 units | 0.24 mL | 12 doses |
| Weeks 5–8+ (maintenance) | 600 mcg | 36 units | 0.36 mL | 8 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 30 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 600 mcg per dose, once or twice daily (14 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| BPC-157 (5 mg) vials | 14 vials | 21 vials |
| Insulin syringes (U-100) | 112 | 168 |
| Bacteriostatic water (10 mL) | 5 × 10 mL | 7 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
BPC-157 is one of the few research-grade peptides with broad consensus protocols across the recovery community. The standard pattern is twice-daily dosing during an active healing window (4–8 weeks), tapering to once-daily maintenance if continued use is desired.
Most users see results within 2–4 weeks for soft-tissue injuries (tendinopathies, partial tears, post-surgical recovery). Gut-protection protocols (IBD, ulcer healing) often show effects faster — within 7–14 days.
Cycle length: 4–8 week loading cycles are standard. Some users run continuous low-dose maintenance for chronic conditions; others cycle 4-on, 4-off. There is no established long-term safety data, so cycling is the conservative default.
Local vs systemic: Subcutaneous injection close to the affected area is favored when feasible. For systemic protocols (gut, vascular), abdomen or thigh injection works fine.
Dosing Protocol
Three common protocol intensities:
- Light/preventive (250 mcg twice daily): Maintenance and prevention. Most-cited research dose for non-acute use.
- Standard (500 mcg twice daily): Standard soft-tissue repair protocol. Most-cited dose for active healing.
- Aggressive (750 mcg twice daily): Acute injury phase, short-term (≤4 weeks). Not validated for sustained use.
Cycle structure: 4-week loading at standard dose for active injury → 4-week maintenance at light dose → 2-week break before re-loading if needed.
Timing: Morning and evening doses, ~12 hours apart. Pre-workout dosing for performance-related protocols. Local injection near injury when feasible.
Stacking: Commonly paired with TB-500 (Wolverine Blend) for connective-tissue protocols — each addresses different aspects of repair.
Oral protocol: BPC-157 is unusually stable in gastric acid; some research uses oral capsule for gut-specific protocols at 500 mcg twice daily.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
BPC-157 is a synthetic 15-amino-acid sequence (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a fragment of body-protection compound found in gastric juice. It survives gastric acid that would destroy most peptides.
Animal models show: VEGFR2 upregulation accelerating angiogenesis at injury sites; modulation of nitric-oxide signaling; promotion of fibroblast migration and tendon-cell outgrowth; anti-inflammatory effects via downregulation of pro-inflammatory cytokines. The compound also stabilizes the gut-brain axis through serotonergic and dopaminergic modulation.
Potential Benefits & Side Effects
Potential Benefits
- Accelerated tendon and ligament healing in rodent models.
- Gastrointestinal protection: ulcer healing, IBD model improvements.
- Neuroprotection in models of TBI, stroke, and chemical neurotoxicity.
- Reduced muscle damage and faster recovery after eccentric exercise.
- Excellent safety profile in animal toxicology — no LD50 reached.
Side Effect Profile
- Generally well-tolerated; no major adverse events in published case series.
- Mild injection-site irritation possible.
- Rare reports of transient mild fatigue or nausea early.
- Theoretical angiogenesis concerns with occult malignancy.
- Long-term human safety data is limited.
Lifestyle Factors
- Inject as close to the affected area as practical when feasible.
- Maintain protein intake (1.2–1.6 g/kg/day) during active healing.
- Avoid NSAIDs during early-phase tendon/ligament healing — they may blunt repair.
- Vitamin C (500–1000 mg/day) supports collagen synthesis.
- Sleep 7–9 hours/night — most tissue repair occurs in deep sleep.
Injection Technique
- Subcutaneous most common; some literature uses intramuscular near the injury.
- Rotate injection sites if dosing twice daily.
- 90° angle with short (4–8 mm) insulin needle.
- Bring solution to room temperature before injecting.
- Hold 5 seconds after full plunger depression.